Top Markets
#1 Black Phoenix Black Phoenix +357.72%
#2 Islamic Coin Islamic Coin +158.16%
#3 Glidr Glidr +58.56%
#4 Cryptopia Cryptopia +20.67%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.42%
#6 Palladium Network Palladium Network +7.87%
#7 Pons Pons +7.21%
#8 Victoria VR Victoria VR +5.38%
#9 Movement Movement +5.24%
#10 Espresso Espresso +4.91%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Kaleido Biosciences, Inc. Kaleido Biosciences, Inc.

Kaleido Biosciences, Inc.

KLDO
Rank in Stocks #42678
Kaleido Biosciences, Inc. is a clinical-stage healthcare firm dedicated to... Kaleido Biosciences, Inc. is a clinical-stage healthcare firm dedicated to pioneering microbiome metabolic therapies. Its pipeline includes specific drug candidates such as KB195 for urea cycle disorders, KB295 targeting ulcerative colitis, KB174 aimed at hepatic encephalopathy, and KB109 for COVID-19. The company is also advancing programs in other significant therapeutic areas, including multi-drug resistant infections, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and various inflammatory bowel conditions. Kaleido maintains strategic collaborations with Institute Gustave Roussy, Washington University, and Janssen. Established in 2015, its headquarters are situated in Lexington, Massachusetts.
Share Price
$0.00001
Last synced: 2026-07-30
Market Cap
$426.00
Change (1 day)
0.00%
Change (1 year)
-90.00%
Country
US
Trade Kaleido Biosciences, Inc. (KLDO)

Category

Healthcare
P/E ratio for Kaleido Biosciences, Inc. (KLDO)
P/E ratio as of 2026 TTM: 0
According to Kaleido Biosciences, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Kaleido Biosciences, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.